CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today announced its confidence in sharing the results from an interim analysis on one of its lead treatment candidates, Berubicin, with the public before the end of the year. Berubicin is a chemotherapy drug that interferes with the DNA of cancer cells to inhibit their growth and potentially shrink tumors. Distinct from other anthracyclines, a clinically trusted class of drugs in use for 60 years against dozens of common cancers, and other traditional chemotherapy drugs, CNS Pharmaceuticals reports that Berubicin has the ability to penetrate the blood-brain barrier and directly target cancer cells in the brain, increasing its potential effectiveness.
In October, the company announced that 229 out of 243 expected patients had already been enrolled in its ongoing study evaluating the effectiveness of Berubicin for recurrent glioblastoma (“GBM”), a highly aggressive and incurable form of brain cancer. The global critical and adaptive trial involves multiple centers and is open-label, randomized and controlled, comparing Berubicin to Lomustine – a drug unapproved for this indication but still used as the standard of care – in adult patients with recurrent GBM (WHO Grade IV) after standard first-line therapy has failed. CNS Pharmaceuticals had set a specific goal to analyze the efficacy data after more than half of the patients enrolled in the study reached the primary endpoint. During this analysis, an independent data safety monitoring board (“DSMB”) closely examines the number of deaths in each treatment group to ensure that Berubicin patients show a significant improvement in overall survival compared to those receiving Lomustine. In addition, other important factors are considered, such as how long patients live without the cancer progressing, response rates and safety. The interim analysis will conclude if Berubicin is at least as effective as Lomustine, in which case the DSMB will make a recommendation that the trial continue.
To view the full press release, visit https://ibn.fm/HPKDP
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
